Cord blood metabolomic profiling in intrauterine growth restriction

Favretto, Donata; Cosmi, Erich; Ragazzi, Eugenio; Visentin, Silvia; Tucci, Marianna; Fais, Paolo; Cecchetto, Giovanni; Zanardo, Vincenzo; Viel, Guido; Ferrara, Santo Davide

doi:10.1007/s00216-011-5540-z

Cited by 111 publications

(92 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, epidemiological studies on twins have shown that the twin with the lower birth weight is more susceptible to developing type 2 diabetes compared to the one with higher birth weight (20). Analysis of umbilical cord blood soon after birth allowed the exploration of differences in the motherfetus interaction that may be involved in this condition (21). The authors showed that the circulating levels of amino acids, including phenylalanine, tryptophan, and methionine, were strikingly different between IUGR and appropriate for gestational age fetuses.…”

Section: Metabolomics Technologies In Clinical Studiesmentioning

confidence: 99%

Metabolomics perspectives in pediatric research

et al. 2013

View full text Add to dashboard Cite

Increasing evidence points toward the critical and long-term involvement of prenatal and early nutrition and lifestyle on later health and disease risk predisposition. Metabolomics is now a well-established top-down systems biology approach that explores the genetic-environment-health paradigm. The generalization of such approaches has opened new research areas to deepen our current understanding of many physiological processes, as well as foods and nutrient functionalities in target populations. It is envisioned that this will provide new avenues toward preventive medicine and prognostic strategies for tailored therapeutic and personalized nutrition management. The development of systems biology approaches and the new generation of biomarker patterns will provide the opportunity to associate complex metabolic regulations with the etiology of multifactorial pediatric diseases. This may subsequently lead to the development of system mechanistic hypotheses that could be targeted with new nutritional personalized concepts. Therefore, this review aims to describe recent applications of metabolomics in preclinical and clinical fields with insights into disease diagnostics/monitoring and improvement of homeostasis metabolic regulation that may be translatable to novel therapeutic and nutrition advances in pediatric research. Over the past decades, awareness about the role of nutrition and lifestyle in health and disease risk management has increased, with key emphasis on the prevention of metabolic disorders, including cardiometabolic diseases and type 2 diabetes (1-3). In parallel, increasing evidence points toward the critical and long-term involvement of early nutrition and lifestyle on later health and disease risk predisposition (4). It therefore becomes pertinent to look at newborn metabolism, development, and nutritional requirements to understand the onset of child and adult physiological conditions. Pregnancy, childbirth, lactation, and human milk composition are influenced by the intake of foods (macro-and micronutrients), which subsequently determine both the short-and long-term health and nutritional outcomes of an individual (5). Therefore, it is essential to build knowledge not only on the metabolic dysregulations but also on the effects of specific foods to comprehensively document the metabolic processes associated with individual health at the different stages of the life cycle (Figure 1). This will allow us to formulate nutritional solutions to improve or circumvent certain metabolic imbalances.The generalization of systems biology approaches has opened new research areas to further our current understanding of many physiological processes, as well as the functionalities of foods and nutrients. In particular, metabolomics is recognized as a powerful top-down systems biology approach to understand the genetic-environment-health paradigm and to identify clinically relevant biomarkers. Its application in clinical studies is envisioned to shed new light on the regulatory processes of complex mammalian sy...

show abstract

Section: Metabolomics Technologies In Clinical Studiesmentioning

confidence: 99%

Metabolomics perspectives in pediatric research

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Targeted metabolomics can provide detailed quantitative information on the metabolic status of an organism, adding to the better characterization of phenotypes associated with metabolic and cardiovascular sequelae over the life course [14]. Metabolic profiling was already used in characterizing maternal plasma and umbilical cord blood metabolomes in conditions such as preterm birth [15], small for gestational age (SGA) [16], low birth weight [17], very low birth weight [18, 19] and intrauterine growth retardation (IUGR) [20-22]. However, a major limitation of available studies are heterogeneous study designs, applied methodology, low sample sizes, the usage of untargeted metabolomic approaches, and the lack of replication of obtained study results [15-23].…”

Section: Introductionmentioning

confidence: 99%

Cord Blood Lysophosphatidylcholine 16: 1 is Positively Associated with Birth Weight

Reichetzeder

Prehn

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Impaired birth outcomes, like low birth weight, have consistently been associated with increased disease susceptibility to hypertension in later life. Alterations in the maternal or fetal metabolism might impact on fetal growth and influence birth outcomes. Discerning associations between the maternal and fetal metabolome and surrogate parameters of fetal growth could give new insight into the complex relationship between intrauterine conditions, birth outcomes, and later life disease susceptibility. Methods: Using flow injection tandem mass spectrometry, targeted metabolomics was performed in serum samples obtained from 226 mother/child pairs at delivery. Associations between neonatal birth weight and concentrations of 163 maternal and fetal metabolites were analyzed. Results: After FDR adjustment using the Benjamini-Hochberg procedure lysophosphatidylcholines (LPC) 14: 0, 16: 1, and 18: 1 were strongly positively correlated with birth weight. In a stepwise linear regression model corrected for established confounding factors of birth weight, LPC 16: 1 showed the strongest independent association with birth weight (CI: 93.63 - 168.94; P = 6.94×10^-11 ). The association with birth weight was stronger than classical confounding factors such as offspring sex (CI: -258.81- -61.32; P = 0.002) and maternal smoking during pregnancy (CI: -298.74 - -29.51; P = 0.017). Conclusions: After correction for multiple testing and adjustment for potential confounders, LPC 16: 1 showed a very strong and independent association with birth weight. The underlying molecular mechanisms linking fetal LPCs with birth weight need to be addressed in future studies.

show abstract

“…In contrast, only very limited data is available relating cord blood metabolomic profiles to birth weight or later growth. Cord blood metabolites have been linked to low birth weight in infants with small for gestational age (SGA) [12] or intrauterine growth restriction (IUGR) [13,14]. Only one study with a small sample size using an untargeted metabolomic approach linked cord blood metabolites to rapid postnatal weight gain [15].…”

Section: Introductionmentioning

confidence: 99%

Cord Blood Metabolome Is Highly Associated with Birth Weight, but Less Predictive for Later Weight Development

Hellmuth

Uhl²,

Standl³

et al. 2017

Obes Facts

View full text Add to dashboard Cite

Background/Aims: Fetal metabolism may be changed by the exposure to maternal factors, and the route to obesity may already set in utero. Cord blood metabolites might predict growth patterns and later obesity. We aimed to characterize associations of cord blood with birth weight, postnatal weight gain, and BMI in adolescence. Methods: Over 700 cord blood samples were collected from infants participating in the German birth cohort study LISAplus. Glycerophospholipid fatty acids (GPL-FA), polar lipids, non-esterified fatty acids (NEFA), and amino acids were analyzed with a targeted, liquid chromatography-tandem mass spectrometry based metabolomics platform. Cord blood metabolites were related to growth factors by linear regression models adjusted for confounding variables. Results: Cord blood metabolites were highly associated with birth weight. Lysophosphatidylcholines C16:1, C18:1, C20:3, C18:2, C20:4, C14:0, C16:0, C18:3, GPL-FA C20:3n-9, and GPL-FA C22:5n-6 were positively related to birth weight, while higher cord blood concentrations of NEFA C22:6, NEFA C20:5, GPL-FA C18:3n-3, and PCe C38:0 were associated with lower birth weight. Postnatal weight gain and BMI z-scores in adolescents were not significantly associated with cord blood metabolites after adjustment for multiple testing. Conclusion: Potential long-term programming effects of the intrauterine environment and metabolism on later health cannot be predicted with profiling of the cord blood metabolome.

show abstract

Cord blood metabolomic profiling in intrauterine growth restriction

Cited by 111 publications

References 41 publications

Metabolomics perspectives in pediatric research

Metabolomics perspectives in pediatric research

Cord Blood Lysophosphatidylcholine 16: 1 is Positively Associated with Birth Weight

Cord Blood Metabolome Is Highly Associated with Birth Weight, but Less Predictive for Later Weight Development

Contact Info

Product

Resources

About